Somewhat Favorable Press Coverage Somewhat Unlikely to Impact Anika Therapeutics (ANIK) Share Price

Media stories about Anika Therapeutics (NASDAQ:ANIK) have been trending somewhat positive recently, according to Accern. The research firm ranks the sentiment of news coverage by monitoring more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Anika Therapeutics earned a daily sentiment score of 0.08 on Accern’s scale. Accern also assigned news headlines about the biotechnology company an impact score of 46.3953852747908 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.

A number of research analysts have weighed in on ANIK shares. Zacks Investment Research downgraded Anika Therapeutics from a “hold” rating to a “sell” rating in a research note on Monday, February 26th. Barrington Research restated a “buy” rating and issued a $57.00 price target on shares of Anika Therapeutics in a research note on Thursday, December 28th. Sidoti assumed coverage on Anika Therapeutics in a research note on Friday, January 26th. They issued a “buy” rating for the company. ValuEngine downgraded Anika Therapeutics from a “buy” rating to a “hold” rating in a research note on Thursday, April 12th. Finally, BidaskClub upgraded Anika Therapeutics from a “hold” rating to a “buy” rating in a research note on Friday, January 26th. One investment analyst has rated the stock with a sell rating, three have given a hold rating and two have assigned a buy rating to the stock. Anika Therapeutics presently has an average rating of “Hold” and a consensus target price of $62.50.

How to Become a New Pot Stock Millionaire

Shares of NASDAQ ANIK opened at $46.46 on Tuesday. Anika Therapeutics has a 12 month low of $42.51 and a 12 month high of $69.81. The company has a market cap of $679.75, a PE ratio of 23.79, a price-to-earnings-growth ratio of 2.94 and a beta of 1.73.

Anika Therapeutics (NASDAQ:ANIK) last issued its earnings results on Wednesday, February 21st. The biotechnology company reported $0.38 EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $0.41 by ($0.03). Anika Therapeutics had a return on equity of 11.91% and a net margin of 28.05%. The business had revenue of $29.39 million for the quarter, compared to the consensus estimate of $29.85 million. During the same quarter in the prior year, the firm posted $0.54 earnings per share. The business’s revenue was up 2.3% compared to the same quarter last year. research analysts anticipate that Anika Therapeutics will post 1.57 earnings per share for the current fiscal year.

WARNING: “Somewhat Favorable Press Coverage Somewhat Unlikely to Impact Anika Therapeutics (ANIK) Share Price” was originally reported by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are reading this article on another website, it was illegally stolen and reposted in violation of United States & international copyright & trademark law. The correct version of this article can be read at https://www.chaffeybreeze.com/2018/04/17/somewhat-favorable-press-coverage-somewhat-unlikely-to-impact-anika-therapeutics-anik-share-price.html.

Anika Therapeutics Company Profile

Anika Therapeutics, Inc is an orthopedic medicines company. The Company is engaged in developing, manufacturing and commercializing products based on its hyaluronic acid (HA) technology. The Company’s orthopedic medicine portfolio includes ORTHOVISC, MONOVISC, and CINGAL, which alleviate pain and restore joint function by replenishing depleted HA, and HYALOFAST, a solid HA-based scaffold to aid cartilage repair and regeneration.

Insider Buying and Selling by Quarter for Anika Therapeutics (NASDAQ:ANIK)

Receive News & Ratings for Anika Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anika Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply